Canagliflozin: A New Therapeutic Option in Patients That Present Postprandial Hyperinsulinemic Hypoglycemia after Roux-en-Y Gastric Bypass: A Pilot Study
Conclusion: Canagliflozin (300 mg) significantly decreased glucose absorption and prevented PHH after 100 g OGTT in patients with RYGB. Our results suggest that canagliflozin could be a new therapeutic option for patients that present PHH after RYGB.Obes Facts
Source: Obesity Facts - Category: Eating Disorders & Weight Management Source Type: research
More News: Calcium | Canagliflozin | Eating Disorders & Weight Management | Gastric Bypass | Gastroenterology | Invokana | Obesity | Pancreas | Study